Since aggregation of amyloids is a mechanism underlying several neurodegenerative diseases [49], repurposing drugs already approved to treat other neurodegenerative diseases may be cost effective and applicable for the treatment of NGLY1‐deficient patients. This evidence concerns the gene NGLY1 and neurodegenerative disease.